Abstract
Eight Pseudomonas aeruginosa clinical strains that produce the clavulanic-acid-inhibited beta-lactamase GES-2 were isolated from patients of a South African hospital from March to July 2000. They were clonally related and each harboured a 150 kb conjugative plasmid carrying a class 1 integron containing a gene cassette encoding GES-2, followed by those for beta-lactamase OXA-5 and an aminoglycoside modifying AAC(3)I-like enzyme. Hence, incidences of infection, several fatal, due to bacteria displaying clavulanate-inhibited resistance to extended-spectrum cephalosporins and reduced susceptibility to imipenem in Pretoria Academic Hospital, South Africa, can be explained, at least in part, by the spread of P. aeruginosa expressing the GES-2 beta-lactamase.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Ceftazidime / pharmacology
-
Cross Infection / epidemiology
-
Cross Infection / microbiology*
-
DNA, Bacterial / analysis
-
Disease Outbreaks*
-
Escherichia coli / genetics
-
Genes, Bacterial
-
Humans
-
Microbial Sensitivity Tests
-
Mutagenesis, Insertional
-
Polymerase Chain Reaction
-
Pseudomonas Infections / epidemiology
-
Pseudomonas Infections / microbiology*
-
Pseudomonas aeruginosa / drug effects
-
Pseudomonas aeruginosa / enzymology
-
Pseudomonas aeruginosa / genetics*
-
Pseudomonas aeruginosa / isolation & purification
-
Random Amplified Polymorphic DNA Technique
-
South Africa / epidemiology
-
beta-Lactam Resistance / genetics
-
beta-Lactamases / biosynthesis
-
beta-Lactamases / genetics*
-
beta-Lactams / pharmacology
Substances
-
DNA, Bacterial
-
beta-Lactams
-
Ceftazidime
-
beta-lactamase GES-2
-
beta-Lactamases